Release Date: 7/2/2015
Expiration Date: 7/1/2016

Review this CME-certified Web Archive below, led by Axel Grothey, MD, for 1.0 AMA PRA Category 1 Credit™, based on the CME-certified live meeting series entitled, Advances in Targeted Therapy: The Role of VEGF and EGFR Inhibitors in mCRC. 

Target Audience
This activity is intended for community and academic medical, surgical, and radiation oncologists; oncology nurses; and other healthcare professionals involved in the treatment of patients with mCRC.

Method of Participation: Internet

Hardware and software needed to participate in the activity: Microsoft Powerpoint (.PPT)

Instructions to receive credit:
To receive credit for this activity, the participant must complete the post-test with a score of 70% or better and the activity evaluation. The certificate will be made available immediately.

Estimated time to complete activity: 1 hour

Contact the Postgraduate Institute for Medicine (PIM) athttp://pimed.com

LEARNING OBJECTIVES: 

At the conclusion of this activity, participants should be better able to:
•    Describe the rationale and role of VEGF- and EGFR-targeted agents in the treatment of mCRC
•    Use molecular testing to guide treatment selection for patients with mCRC
•    Assess the safety, efficacy and when it is appropriate to incorporate current targeted therapies into the treatment armamentarium for mCRC
•    Assses emerging targeted therapy options in mCRC


FACULTY 
Chairperson

Axel Grothey, MD
Professor of Oncology
Mayo Clinic – Rochester
Rochester, Minnesota

Physician Continuing Medical Education
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Axel Grothey, MD Reported a financial interest/relationship or affiliation in the form of Advisory Board: Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; sanofi US; Contracted Research: Bayer Pharmaceuticals Corporation; Daiichi-Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Morphotek, Inc.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Ronald Viggiani, MD; Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
 

1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter     
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners


Fee Information
There is no fee for this educational activity.

Jointly provided by

This activity is supported by an independent educational grant from Genentech and Lilly.